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Background-—Fibroblast growth factor-23 (FGF-23) is a hormone involved in phosphorous regulation and vitamin D metabolism
that may be associated with cardiovascular risk, and it is a potential target for intervention. We tested whether elevated FGF-23 is
associated with incident coronary heart disease, heart failure, and cardiovascular mortality, even at normal kidney function.
Methods and Results-—A total of 11 638 Atherosclerosis Risk In Communities study participants, median age 57 at baseline
(1990–1992), were followed through 2010. Cox regression was used to evaluate the independent association of baseline serum
active FGF-23 with incident outcomes. Models were adjusted for traditional cardiovascular risk factors and estimated glomerular
filtration rate. During a median follow-up of 18.6 years, 1125 participants developed coronary heart disease, 1515 developed heart
failure, and 802 died of cardiovascular causes. For all 3 outcomes, there was a threshold, whereby FGF-23 was not associated with
risk at <40 pg/mL but was positively associated with risk at >40 pg/mL. Compared with those with FGF-23 <40 pg/mL, those in
the highest FGF-23 category (≥58.8 pg/mL) had a higher risk of incident coronary heart disease (adjusted hazard ratio, 95% CIs:
1.65, 1.40 to 1.94), heart failure (1.75, 1.52 to 2.01), and cardiovascular mortality (1.65, 1.36 to 2.01). Associations were
modestly attenuated but remained statistically significant after further adjustment for estimated glomerular filtration rate.
In stratified analyses, similar results were observed in African Americans and among persons with normal kidney function.
Conclusions-—High levels of serum FGF-23 were associated with increased risk of coronary heart disease, heart failure, and
cardiovascular mortality in this large, biracial, population-based cohort. This association was independent of traditional
cardiovascular risk factors and kidney function. ( J Am Heart Assoc. 2014;3:e000936 doi: 10.1161/JAHA.114.000936)
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F ibroblast growth factor 23 (FGF-23) is a hormone that issecreted primarily by osteocytes and to a lesser extent
by osteoblasts. It is involved in the regulation of phosphorus
homeostasis, vitamin D metabolism, and bone mineralization.
Specifically, it induces urinary phosphorous excretion, inhibits
activation of calcitriol [1,25(OH)2D], and suppresses parathy-
roid hormone (PTH) synthesis.1–3 Levels of FGF-23 are
correlated inversely with renal function,4,5 and in patients
with chronic kidney disease (CKD), elevated serum FGF-23
levels predict the progression of renal failure,6 and death.7,8
The potential role of FGF-23 in the development of
cardiovascular disease, particularly independent of kidney
function, is unclear. FGF-23 may influence cardiovascular risk
through the CKD or vitamin D pathways; CKD is an
established risk factor for cardiovascular disease,9 and
accruing evidence suggests that low levels of vitamin D may
increase cardiovascular risk.10 Furthermore, recent experi-
mental work in rodent models suggests FGF-23 may have a
direct pathophysiologic role in inducing left ventricular
hypertrophy (LVH),11 a marker of cardiac remodeling associ-
ated with increased risk of sudden cardiac death and
progression to heart failure (HF).12 Several studies have
shown FGF-23 to be associated with cardiovascular events
among patients with CKD13–16 and in those with prevalent
coronary heart disease (CHD).17 In the general population,
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information is more limited,18,19 although it is suggestive of an
association, particularly among individuals with impaired
kidney function.18,19 Information is lacking for those with
normal renal function, and prior studies have not had
adequate power to examine these associations among African
Americans.
Using data from the prospective, community-based Ath-
erosclerosis Risk In Communities (ARIC) Study, we tested the
hypothesis that active, intact FGF-23 is positively associated
with risk of incident CHD, HF, and cardiovascular mortality,
independent of traditional cardiovascular risk factors and
markers of kidney function.
Methods
Study Population
The ARIC study is a population-based prospective cohort of
15 792 men and women (aged 45 to 64 years at baseline)
who, between 1987 and 1989, were recruited from 4 US
communities: Forsyth County, North Carolina; Jackson, Mis-
sissippi; suburbs of Minneapolis, Minnesota; and Washington
County, Maryland.20 A total of 4 cohort reexaminations have
taken place: 1990–1992 (visit 2), 1993–1995 (visit 3), 1996–
1998 (visit 4), and 2011–2013 (visit 5). Local institutional
review boards approved the ARIC protocol, and all participants
gave informed consent.
Serum FGF-23 was measured in samples collected at ARIC
visit 2 (1990–1992); we are therefore using visit 2, which was
attended by 14 348 participants, as “baseline” for the present
analysis. Excluded from the analysis are participants who had
prevalent CHD or HF at visit 2 (n=1368), self-identified as
neither African American nor white and African Americans
from the Minnesota and Maryland centers (n=85), had
missing FGF-23 data (n=751), and had missing data on any
covariate (n=506). Our final analytic sample included 11 638
participants.
FGF-23 and Other Variables
At visit 2, ARIC participants underwent interviews, fasting
venipuncture, and measurement of blood pressure and
anthropometrics. Trained interviewers ascertained basic
demographic data, medical history, smoking status, and
medication use. Participants were asked to bring to the visit
all medications, vitamins, and supplements taken in the
2 weeks before the examination; all medication names were
transcribed and coded. Physical activity (Baecke21 question-
naire) was not assessed at visit 2, so values from visit 1 were
carried forward. Height and weight were measured, and body
mass index (BMI) calculated as weight/height2 (kg/m2).
Sitting blood pressure was measured in triplicate with a
random-zero sphygmomanometer; the mean of the latter 2
measurements were used in this analysis. Diabetes was
defined by fasting blood glucose >126 mg/dL, nonfasting
glucose >200 mg/dL, a self-report of physician diagnosis, or
current medication use for diabetes. Left ventricular hyper-
trophy was determined by the Cornell definition, based on
12-lead electrocardiograms.22
Fasting (12-hour) blood samples were drawn, and plasma
and serum were frozen at 70°C until analyzed. Intact FGF-23
was measured, in singlicate, in serum using a 2-site ELISA
(FGF-23 ELISA Kit, Kainos Laboratories, Inc) at the Advanced
Research and Diagnostic Laboratory, University of Minnesota,
Minneapolis, Minnesota, in 2012–2013. The coefficient of
variation (CV) for FGF-23 based on ARIC blind duplicate
samples was 16.6%, while the CV from internal laboratory QC
samples was 8.8% at 41.4 pg/mL. Serum phosphorus was
measured in 2012–2013 on a Roche Modular P Chemistry
Analyzer using a colorimetric method (CV=3%), and serum
B-type natriuretic peptide (NT-proBNP) and serum high-
sensitivity troponin T (hs-TnT) were measured using sandwich
immunoassay methods on a Roche Elecsys 2010 Analyzer
(Roche Diagnostics Corporation). Lipids were measured at the
time of ARIC visit 2 (1990–1992). Total plasma cholesterol23
and triglycerides24 were determined via enzymatic methods.
High-density lipoprotein cholesterol (HDL-C) was measured
after dextran-magnesium precipitation,25 and the Friedewald
equation26 was used to calculate low-density lipoprotein
cholesterol (LDL-C) in those with triglyceride levels <400 mg/
dL. Cystatin C was measured in 2012–2013 using the Gentian
cystatin C reagent on the Roche Modular P Chemistry
analyzer, and serum creatinine was measured in 1990–1992
using a modified kinetic Jaffe reaction. Estimated glomerular
filtration rate (eGFR) was calculated using the 2012 CKD EPI
equation, which incorporates both cystatin C and creatinine.27
eGFR was categorized according to established clinical cut-
points: ≥90, 60 to 89, and 15 to 59 mL/min per 1.73 m2. No
participants in our sample had an eGFR <15. Urine was not
collected at ARIC visit 2 but was available at visit 4. Urinary
creatinine was measured by the Jaffe method and albumin by
a nephelometric method either on the Dade Behring BN100
(Dade Behring, Inc, Deerfield, IL) or Beckman Image
Nephelometer. The albumin–creatinine ratio (ACR) was
calculated.
Prevalent CHD was defined by self-reported prior physician
diagnosis of MI or coronary revascularization, prevalent MI by
12-lead ECG at visit 1, or an incident-adjudicated CHD event
between ARIC visits 1 and 2. Preexisting HF was defined by
any of the following: (1) an affirmative response to, “Were any
of the medications you took during the last 2 weeks for heart
failure?” (2) stage 3 or “manifest heart failure” according to
Gothenburg criteria,28,29 or (3) incident HF hospitalization
between ARIC visits 1 and 2.
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Incident cardiovascular events and deaths through Decem-
ber 31, 2010, were identified through (1) annual telephone
calls to ARIC cohort participants (or proxy), (2) active
surveillance of local hospital discharge indexes, (3) search of
state death records, and (4) linkage to the National Death
Index. ARIC criterion and procedures for validating potential
CHD events have been described previously.30 In brief,
incident CHD was defined as the first occurrence of a
validated definite or probable hospitalized MI or a definite
CHD death. HF incidence was defined as the first occurrence
of either a hospitalization that included an International
Classification of Diseases, 9th Revision (ICD-9) discharge
code of 428 (428.0 to 428.9) among the primary or
secondary diagnoses or a death certificate with an ICD-9
code of 428 or an ICD-10 code of I50 among any of the
listed diagnoses or underlying causes of death.29 Cardiovas-
cular mortality was defined as death with ICD-9 code 401-
459 or ICD-10 code I10-I99.
Statistical Analysis
Characteristics of participants at visit 2 are described using
means and proportions, stratified by categories of FGF-23.
Pearson’s correlation coefficients between key biomarkers
are also provided. For the primary analysis, Cox proportional
hazards regression was used to determine associations
between FGF-23 and risk of incident CHD, HF, and
cardiovascular mortality. Restricted cubic splines were used
to explore the dose–response association between FGF-23
and outcomes and to aid in selecting the most appropriate
exposure modeling. For all outcomes, there appeared to be a
threshold whereby FGF-23 was unrelated to risk at levels
<40 pg/mL but was associated with greater risk beyond
that point. To convey this association, we used levels
<40 pg/mL as the reference category (contains 45.3% of
the analytic sample). Levels ≥40 pg/mL were divided into
quartiles (each quartile contains 13.7% of the full study
population). Given inherent interest, we also report the linear
association (per 1 SD) between FGF-23 and outcomes. FGF-
23 is a novel biomarker; as such, there are presently no cut-
points used clinically for elevated FGF-23. Our first model
adjusted for basic demographics (age, sex, and race). Model
2 additionally adjusted for education, physical activity,
smoking status, and BMI. Model 3 further adjusted for
prevalent diabetes, systolic BP, hypertension medication use,
lipid medication use, LDL-C, and HDL-C. In additional
models, we also adjusted, separately, for eGFR, serum
phosphorus, PTH, NT-proBNP, hs-TnT, and LVH. Cross-
product terms were used to evaluate whether age, race,
sex, or eGFR modified associations between FGF-23 cate-
gories and outcomes. The proportional hazards assumption
was evaluated by inspection of ln(ln) survival curves for
FGF-23 categories. SAS version 9.3 was used.
Results
Our analytic sample included a total of 11 638 participants
(female participants 57%, African American 25%, and mean age
57 years). Mean (SD) FGF-23 was 43.9 (16.4) pg/mL.
Levels of FGF-23 were correlated positively with serum
phosphorous (r=0.11) and PTH (r=0.11) and inversely with
eGFR (r=0.25). Relative to participants with FGF-23
concentrations below 40 pg/mL, those in the highest
category (≥58.8 pg/mL) were slightly older, more likely to
be African American, and overall had a worse cardiovascular
risk factor profile, particularly in regard to hypertension
and CKD (Table 1). For example, 9.3% of participants in
the top category of FGF-23 had an eGFR <60 mL/min
per 1.73 m2, while among participants in the lowest category
of FGF-23 only 1.0% had an eGFR <60 mL/min per 1.73 m2.
Incident CHD
During a median of 18.6 (maximum 20.9) years of follow-up,
1125 incident CHD events accrued (median [SD] time to
event 10.2 [5.4] years). FGF-23 was positively and signifi-
cantly associated with risk of incident CHD when modeled
linearly (per 1 SD), regardless of level of adjustment
(Table 2). However, as illustrated in the restricted cubic
spline models (Figure – Panel A), there was a threshold
effect whereby there was no association between FGF-23
and risk at levels <40 pg/mL, but at >40 pg/mL there was
a positive association. Hence, the reference group, which
contains 45.3% of the full analytic sample, includes partic-
ipants with FGF-23 concentrations <40 pg/mL. Levels
>40 pg/mL were split into quartiles. After demographic
adjustments, people in the highest category of FGF-23
(≥58.8 pg/mL) were at 1.65 (95% CI 1.40 to 1.94)
times greater risk of incident CHD, relative to those at
<40 pg/mL (Table 2). The association was similar with
additional adjustment for behaviors (model 2: 1.63 [1.38 to
1.92]) and only modestly attenuated with further adjustment
for cardiovascular risk factors (model 3: 1.44 [1.22 to 1.70])
and eGFR (model 4: 1.32 [1.11 to 1.56]). Results
were essentially unchanged when model 4 was additionally
adjusted for serum phosphorous (hazard ratio [HR] 1.30
[1.09 to 1.54]) and PTH (HR 1.31 [1.10 to 1.55]).
In sensitivity analyses when follow-up time was restricted
to the first 5 years, a total of 229 events accrued (53 in
the upper category), and results were somewhat stronger:
model 1: 1.89 (1.34 to 2.66) and model 4: 1.40 (0.97 to
2.02).
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There was no evidence of interaction by age, sex, race, or
eGFR on the association between FGF-23 and incident CHD.
Given inherent interest, race- and eGFR-stratified results are
presented in Tables 3 and 4, respectively. Associations were
qualitatively stronger in African Americans, relative to whites. It
is important to note that in the analytic sample, only 309 ARIC
participants had an eGFR <60 mL/min per 1.73 m2 at visit 2.
Thus, power is more limited when restricted to this group.
Table 1. Participant Characteristics by Serum FGF-23 Category: The ARIC Study 1990–1992
Serum FGF-23 (pg/mL) Group 1 Group 2 Group 3 Group 4 Group 5
Median 32.8 42.2 47.2 53.5 67.2
Range 2.9 to 40.0 40.1 to 44.6 44.7 to 50.1 50.2 to 58.7 58.8 to 481.0
N total (%) 5272 (45.3) 1591 (13.7) 1592 (13.7) 1591 (13.7) 1592 (13.7)
Demographics
Age, meanSD y 56.35.7 56.65.6 56.95.6 56.95.7 57.55.7
Female, n (%) 3131 (59.4) 885 (55.6) 888 (55.8) 872 (54.8) 916 (57.5)
African American, n (%) 1237 (23.5) 361 (22.7) 399 (25.1) 412 (25.9) 426 (26.8)
Education, n (%)
<High school 1002 (19.0) 320 (20.1) 323 (20.3) 339 (21.3) 357 (22.4)
High school 2288 (43.4) 642 (40.4) 646 (40.6) 638 (40.1) 653 (41.0)
>High school 1982 (37.6) 629 (39.5) 623 (39.1) 614 (38.6) 582 (36.6)
Behavioral characteristics
Sport index, meanSD 2.50.8 2.50.8 2.40.8 2.40.8 2.40.8
Smoking, n (%)
Current 1263 (24.0) 325 (20.4) 335 (21.0) 324 (20.4) 280 (17.6)
Former 1924 (36.5) 564 (35.5) 607 (38.1) 600 (37.7) 605 (38.0)
Never 2085 (39.6) 702 (44.1) 650 (40.8) 667 (41.9) 707 (44.4)
Physiologic characteristics
BMI, kg/m2SD 27.25.2 27.75.1 28.15.2 28.25.2 29.15.8
Prevalent diabetes, n (%) 613 (11.6) 169 (10.6) 218 (13.7) 218 (13.7) 274 (17.3)
Prevalent hypertension, n (%) 1463 (27.8) 492 (31.0) 555 (35.0) 583 (36.7) 707 (44.5)
Systolic BP, mm HgSD 12018 12118 12118 12219 12319
Diastolic BP, mm HgSD 7210 7210 7310 7311 7310
Hypertension medications, n (%) 1188 (22.5) 422 (26.5) 495 (31.1) 496 (31.2) 657 (41.3)
Lipid-lowering medications, n (%) 229 (4.4) 71 (4.5) 97 (6.1) 96 (6.1) 110 (6.9)
HDL-C, mg/dLSD 52.317.0 50.216.6 49.416.4 48.815.9 48.316.6
LDL-C, mg/dLSD 13136 13536 13436 13536 13738
Triglycerides, mg/dLSD 11960 12866 13164 13467 14370
hs-CRP, mg/dL 4.07.2 3.75.4 4.47.1 4.06.1 4.96.9
PTH, pg/mL 40.615.1 41.415.9 42.315.5 42.816.9 44.622.5
Phosphorous, mg/dL 3.50.5 3.50.5 3.60.5 3.60.5 3.60.5
eGFR*, mL/min per 1.73 m2SD 95.414.4 92.814.4 91.315.0 89.615.8 84.218.5
eGFR* category, n (%)
>90 mL/min per 1.73 m2 3491 (66.2) 938 (59.0) 882 (55.4) 808 (50.8) 617 (38.8)
60 to 90 mL/min per 1.73 m2 1730 (32.8) 630 (39.6) 682 (42.8) 724 (45.5) 827 (52.0)
<60 mL/min per 1.73 m2 51 (1.0) 23 (1.5) 28 (1.8) 59 (3.7) 148 (9.3)
ARIC indicates Atherosclerosis Risk In Communities; FGF-23, fibroblast growth factor-23; BMI, body mass index; BP, blood pressure; HDL-C, high-density lipoprotein cholesterol;
LDL-C, low-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; PTH, parathyroid hormone; eGFR, estimated glomerular filtration rate.
*eGFR was estimated using the 2012 Inker equation, which incorporates both cystatin C and serum creatinine.
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A total of 1515 incident HF events occurred through amedian of
18.6 years of follow-up (maximum 20.9 years). Among those
who experienced events, median (SD) time to event was 11.4
(5.3) years. Whenmodeled continuously (per 1 SD), FGF-23 was
positively associated with HF risk, regardless of degree of
adjustment (Table 2). A threshold effect was also observed
between FGF-23 and risk of incident HF (Figure – Panel B).
Comparedwith those in the referent category (<40 pg/mL), the
HR (95% CI) among those in the top category of FGF-23
(≥58.8 pg/mL) was 1.75 (1.52 to 2.01) after demographic
adjustments (Table 2). Further adjustment for behaviors (1.63
[1.42 to 1.88]), cardiovascular risk factors (1.46 [1.27 to 1.68]),
and eGFR (1.30 [1.13 to 1.51]) modestly attenuated the
association. Also adjusting for serumphosphorous and PTH had
little impact on theHRs: 1.27 (1.09 to1.47) for phosphorous and
1.30 (1.12 to 1.51) for PTH. Results were stronger in sensitivity
analyses when follow-up time was restricted to the first 5 years
of follow-up: N events total/top category (230/62); model 1:
2.28 (1.63 to 3.18) and model 4: 1.48 (1.03 to 2.11).
The relation between FGF-23 and incident HF was not
modified by age, sex, or race, although qualitatively associ-
ations were somewhat stronger in blacks than in whites
(Table 3). There was no statistically significant interaction of
the HF and FGF-23 association by eGFR category; however,
stratified results are presented in Table 4.
Incident Cardiovascular Mortality
A total of 802 participants died of cardiovascular causes
during follow-up. The median time to event was 11.2 (SD 4.1)
years. A positive association was observed between FGF-23
when modeled per 1 SD and cardiovascular mortality. Similar
to other outcomes, there was evidence of a threshold
association (Figure – Panel C). Relative to those with FGF-
23 concentrations <40 pg/mL, those in the highest category
(≥58.8 pg/mL) had a HR for cardiovascular mortality of 1.65
(1.36 and 2.01) after demographic adjustments (model 1)
(Table 2). In the fully adjusted model (model 4), the HR (top
versus bottom category) for cardiovascular mortality was 1.28
(1.04 to 1.57). Results were similar when serum phosphorus
Table 2. Serum FGF-23 and Risk of Incident CHD, HF, and Cardiovascular Mortality: The ARIC Study 1990–2010
Serum FGF-23 (pg/mL) Group 1 Group 2 Group 3 Group 4 Group 5 Per 1 SD (16.40 pg/mL)
Median 32.8 42.2 47.2 53.5 67.2
Range 2.9 to 40.0 40.1 to 44.6 44.7 to 50.1 50.2 to 58.7 58.8 to 481.0
N total (%) 5272 (45.3) 1591 (13.7) 1592 (13.7) 1591 (13.7) 1592 (13.7)
Incident CHD
N events 438 141 145 183 218 1125
Model 1 1.00 (Ref) 1.05 (0.87, 1.27) 1.05 (0.87, 1.27) 1.34 (1.13, 1.60) 1.65 (1.40, 1.94) 1.14 (1.09, 1.18)
Model 2 1.00 (Ref) 1.06 (0.88, 1.28) 1.06 (0.88, 1.29) 1.35 (1.13, 1.60) 1.63 (1.38, 1.92) 1.12 (1.08, 1.17)
Model 3 1.00 (Ref) 1.02 (0.84, 1.23) 1.00 (0.83, 1.21) 1.24 (1.04, 1.48) 1.44 (1.22, 1.70) 1.11 (1.06, 1.16)
Model 4 1.00 (Ref) 1.01 (0.83, 1.22) 0.98 (0.81, 1.19) 1.19 (1.00, 1.42) 1.32 (1.11, 1.56) 1.08 (1.03, 1.13)
Incident HF
N events 583 183 221 220 308 1515
Model 1 1.00 (Ref) 1.04 (0.88, 1.22) 1.21 (1.03, 1.41) 1.22 (1.05, 1.43) 1.75 (1.52, 2.01) 1.15 (1.11, 1.18)
Model 2 1.00 (Ref) 1.04 (0.88, 1.23) 1.19 (1.02, 1.39) 1.21 (1.03, 1.41) 1.63 (1.42, 1.88) 1.12 (1.09, 1.15)
Model 3 1.00 (Ref) 1.04 (0.88, 1.23) 1.14 (0.97, 1.33) 1.14 (0.97, 1.33) 1.46 (1.27, 1.68) 1.11 (1.07, 1.15)
Model 4 1.00 (Ref) 1.03 (0.87, 1.21) 1.12 (0.96, 1.31) 1.08 (0.92, 1.26) 1.30 (1.13, 1.51) 1.08 (1.04, 1.13)
Incident cardiovascular mortality
N events 295 114 110 126 157 802
Model 1 1.00 (Ref) 1.26 (1.01, 1.56) 1.15 (0.92, 1.43) 1.32 (1.07, 1.62) 1.65 (1.36, 2.01) 1.15 (1.10, 1.20)
Model 2 1.00 (Ref) 1.27 (1.03, 1.58) 1.17 (0.94, 1.46) 1.33 (1.08, 1.64) 1.65 (1.36, 2.01) 1.14 (1.10, 1.19)
Model 3 1.00 (Ref) 1.26 (1.02, 1.55) 1.10 (0.89, 1.38) 1.25 (1.02, 1.55) 1.51 (1.24, 1.84) 1.13 (1.08, 1.19)
Model 4 1.00 (Ref) 1.24 (0.99, 1.54) 1.07 (0.86, 1.34) 1.14 (0.92, 1.41) 1.28 (1.04, 1.57) 1.08 (1.02, 1.15)
Model 1: Adjusted for age, sex, and race. Model 2: Adjusted for model 1 plus education, physical activity, smoking, and BMI. Model 3: Adjusted for model 2 plus prevalent diabetes, systolic
BP, HTN medication use, lipid medication use, LDL cholesterol, and HDL cholesterol. Model 4: Adjusted for model 3 plus eGFR category (Inker 2012 cystatin C and creatinine; 3-level
category). FGF-23 indicates fibroblast growth factor-23; CHD, coronary heart disease; HF, heart failure; ARIC, Atherosclerosis Risk In Communities; BMI, body mass index; BP, blood
pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; HTN, hypertension; LDL, low-density lipoprotein.
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was included with model 4 covariates (1.23 [1.01 to 1.52])
and when PTH was included with model 4 covariates (1.28
[1.04 to 1.58]). Restricting follow-up time to the first 5 years
did yield stronger magnitudes of association: N events total/
top category (96/30); model 1: 2.45 (1.50 to 3.99) and model
4: 1.61 (0.96 to 2.70).
There were no statistically significant interactions by age,
or sex. The association between FGF-23 and cardiovascular
mortality was stronger among blacks relative to whites (P-
interaction model 1=0.02; P-interaction model 4=0.02)
(Table 3). eGFR category modified the association between
FGF-23 and cardiovascular mortality in demographic-adjusted
models (P-interaction=0.05) but not after accounting for
behaviors and cardiovascular risk factors. eGFR-stratified
results are presented in Table 4.
Sensitivity Analyses
In sensitivity analyses, we explored the impact of adjusting for
eGFR as a continuous variable and estimating GFR by using
alternate equations. Results were similar regardless of how
eGFR was modeled or calculated (data not shown). We also
adjusted (separately) for ln(NT-proBNP) and ln(hs-TnT) and
LVH presence by using the Cornell criteria. The results were
attenuated only slightly (data not shown). Notably, the ARIC
population was relatively young at visit 2, when the serum
used for FGF-23 measurement was collected, and only 2% of
the sample had LVH according to the Cornell criteria.
In order to further isolate our sample to people free of
renal impairment, we restricted our analysis to participants
who attended visit 4 (when urine was collected), were at visit
4 free of prevalent CHD or HF, had an albumin-to-creatinine
ratio of >30 at visit 4, and an eGFR ≥60 at visit 2 (analytic
sample=8397). After adjustment for cardiovascular risk
factors, the HR’s comparing those in the top FGF-23 category
to those with FGF-23 <40 pg/mL were as follows: MI: 1.36
(1.06, 1.76); HF: 1.29 (1.04, 1.60), cardiovascular mortality:
1.57 (1.15, 2.14).
Discussion
In this large, biracial, population-based cohort, we observed a
threshold effect in the association of FGF-23 and risk of
incident CHD, HF, and cardiovascular mortality. A positive
association was present between FGF-23 and risk of
outcomes at FGF-23 levels above 40 pg/mL, whereas at
levels <40 pg/mL there was no association. Relative to
participants at <40 pg/mL, those in the highest category of
FGF-23 (≥58.8 pg/mL) were at 44% greater risk of incident
CHD, 46% greater risk of HF, and 51% greater risk of
cardiovascular mortality, after adjustment for demographics,
behaviors, and traditional cardiovascular risk factors. These
associations were independent of serum phosphorus, and
additional adjustment for markers of kidney function only
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Figure. Association of serum FGF-23 with risk of incident CHD,
HF, and cardiovascular mortality: the ARIC Study 1987–2010.
Biomarkers modeled as restricted cubic splines with knots at the
5th, 27.5th, 50th, 72.5th, and 95th percentiles and are adjusted
for age, sex, and race. Black line represents hazard ratio; gray
shaded area, 95% confidence interval. A, FGF-23 and incident
CHD. B, FGF-23 and incident HF. C, FGF-23 and incident
cardiovascular mortality. ARIC indicates Atherosclerosis Risk In
Communities; CHD, coronary heart disease; FGF-23, fibroblast
growth factor-23; HF, heart failure.
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when our analysis was restricted to individuals estimated
to have normal kidney function (eGFR ≥90 mL/min per
1.73 m2), elevated FGF-23 was associated with greater risk of
incident CHD and HF independent of traditional cardiovascu-
lar risk factors. Finally, the associations were at least as
strong, and in some cases qualitatively stronger, among
African Americans, a relatively understudied group. These
findings extend the results of prior studies by showing that
FGF-23 may be a risk factor for cardiovascular disease and
mortality among those with normal kidney function, that
elevated FGF-23 is associated with greater risk of CHD, and
by having adequate power to examine the association
between FGF-23 and outcomes in African Americans.
There are several mechanisms through which elevated
FGF-23 may increase the risk of CHD and HF. First, FGF-23
may directly contribute to remodeling of the left ventricle by
Table 3. Serum FGF-23 and Risk of Incident CHD, HF, and Cardiovascular Mortality Stratified by Race: The ARIC Study 1990–2010
Serum FGF-23 (pg/mL) Group 1 Group 2 Group 3 Group 4 Group 5 Per 1 SD (16.40 pg/mL)
Median 32.8 42.2 47.2 53.5 67.2
Range 2.9 to 40.0 40.1 to 44.6 44.7 to 50.1 50.2 to 58.7 58.8 to 481.0
N total
Blacks 1237 361 399 412 426 2835
Whites 4035 1230 1193 1179 1166 8803
Incident CHD
African Americans
N events 112 46 33 56 71 318
Model 1 1.00 (Ref) 1.39 (0.98 to 1.96) 0.90 (0.61 to 1.33) 1.48 (1.07 to 2.04) 1.88 (1.39 to 2.53) 1.26 (1.16 to 1.38)
Model 2 1.00 (Ref) 1.41 (0.99 to 1.99) 0.90 (0.61 to 1.33) 1.27 (0.91 to 1.76) 1.41 (1.03 to 1.94) 1.13 (1.03 to 1.24)
Whites
N events 326 95 112 127 147 807
Model 1 1.00 (Ref) 0.94 (0.75 to 1.18) 1.11 (0.89 to 1.37) 1.29 (1.05 to 1.59) 1.56 (1.28 to 1.89) 1.11 (1.05 to 1.17)
Model 2 1.00 (Ref) 0.89 (0.71 to 1.12) 1.01 (0.81 to 1.25) 1.17 (0.95 to 1.44) 1.28 (1.04 to 1.57) 1.06 (0.99 to 1.13)
Incident HF
African Americans
N events 184 50 75 73 114 496
Model 1 1.00 (Ref) 0.91 (0.67 to 1.25) 1.26 (0.96 to 1.64) 1.19 (0.91 to 1.56) 1.88 (1.49 to 2.38) 1.28 (1.19 to 1.37)
Model 2 1.00 (Ref) 0.97 (0.71 to 1.33) 1.23 (0.94 to 1.61) 0.97 (0.74 to 1.29) 1.32 (1.02 to 1.69) 1.12 (1.04 to 1.21)
Whites
N events 399 133 146 147 194 1019
Model 1 1.00 (Ref) 1.09 (0.90 to 1.33) 1.18 (0.98 to 1.43) 1.24 (1.03 to 1.50) 1.67 (1.41 to 1.99) 1.12 (1.08 to 1.17)
Model 2 1.00 (Ref) 1.07 (0.88 to 1.30) 1.08 (0.89 to 1.30) 1.12 (0.93 to 1.36) 1.30 (1.09 to 1.56) 1.07 (1.02 to 1.12)
Incident cardiovascular mortality
African Americans
N events 97 43 55 51 74 320
Model 1 1.00 (Ref) 1.47 (1.03 to 2.11) 1.71 (1.23 to 2.39) 1.51 (1.07 to 2.12) 2.18 (1.61 to 2.96) 1.30 (1.22 to 1.40)
Model 2 1.00 (Ref) 1.48 (1.03 to 2.13) 1.65 (1.18 to 2.31) 1.21 (0.86 to 1.72) 1.58 (1.14 to 2.18) 1.15 (1.07 to 1.24)
Whites
N events 198 71 55 75 83 482
Model 1 1.00 (Ref) 1.16 (0.88 to 1.52) 0.87 (0.65 to 1.17) 1.23 (0.94 to 1.60) 1.38 (1.06 to 1.78) 1.07 (0.99 to 1.16)
Model 2 1.00 (Ref) 1.13 (0.86 to 1.49) 0.78 (0.58 to 1.06) 1.10 (0.84 to 1.44) 1.11 (0.85 to 1.45) 1.00 (0.91 to 1.10)
Model 1: Adjusted for age, sex, and race. Model 2: Adjusted for model 1 plus education, physical activity, smoking, BMI, prevalent diabetes, systolic BP, HTN medication use, lipid
medication use, LDL cholesterol, HDL cholesterol, and eGFR category (Inker 2012 cystatin C and creatinine; 3-level category). ARIC indicates Atherosclerosis Risk in Communities; BMI,
body mass index; BP, blood pressure; CHD, coronary heart disease; eGFR, estimated glomerular filtration rate; FGF-23, fibroblast growth factor-23; HDL, high-density lipoprotein; HF, heart
failure; HTN, hypertension; LDL, low-density lipoprotein.
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Table 4. Serum FGF-23 and Risk of Incident CHD, HF, and Cardiovascular Mortality Stratified by Baseline Kidney Function:
The ARIC Study 1990–2010
Serum FGF-23 (pg/mL) Group 1 Group 2 Group 3 Group 4 Group 5 Per 1 SD (16.40 pg/mL)
Median 32.8 42.2 47.2 53.5 67.2
Range 2.9 to 40.0 40.1 to 44.6 44.7 to 50.1 50.2 to 58.7 58.8 to 481.0
N total
eGFR ≥90 3491 938 882 808 617 6736
eGFR 60 to <90 1730 630 682 724 827 4593
eGFR <60 51 23 28 59 148 309
Incident CHD
eGFR ≥90
N events 273 57 50 68 75 523
Model 1 1.00 (Ref) 0.75 (0.56 to 0.99) 0.70 (0.52 to 0.95) 1.05 (0.80 to 1.36) 1.56 (1.21 to 2.01) 1.07 (0.97 to 1.17)
Model 2 1.00 (Ref) 0.76 (0.57 to 1.02) 0.68 (0.50 to 0.92) 1.04 (0.79 to 1.35) 1.50 (1.16 to 1.94) 1.06 (0.96 to 1.17)
eGFR 60 to <90
N events 157 81 91 99 107 535
Model 1 1.00 (Ref) 1.46 (1.12 to 1.91) 1.44 (1.11 to 1.86) 1.49 (1.16 to 1.92) 1.45 (1.13 to 1.85) 1.10 (1.03 to 1.16)
Model 2 1.00 (Ref) 1.38 (1.06 to 1.81) 1.38 (1.06 to 1.79) 1.36 (1.05 to 1.75) 1.28 (1.00 to 1.64) 1.07 (1.00 to 1.14)
eGFR <60
N events 8 3 4 16 36 67
Model 1 1.00 (Ref) 0.97 (0.26 to 3.70) 0.92 (0.28 to 3.07) 1.87 (0.80 to 4.39) 1.60 (0.74 to 3.45) 1.16 (1.02 to 1.32)
Model 2 1.00 (Ref) 1.04 (0.26 to 4.14) 0.89 (0.26 to 3.01) 1.74 (0.72 to 4.20) 1.46 (0.66 to 3.25) 1.12 (0.97 to 1.30)
Incident HF
eGFR ≥90
N events 322 72 93 85 87 659
Model 1 1.00 (Ref) 0.81 (0.63 to 1.05) 1.10 (0.87 to 1.38) 1.13 (0.89 to 1.44) 1.49 (1.17 to 1.89) 1.09 (1.00 to 1.18)
Model 2 1.00 (Ref) 0.84 (0.65 to 1.09) 1.04 (0.83 to 1.31) 1.10 (0.86 to 1.40) 1.34 (1.06 to 1.71) 1.06 (0.98 to 1.16)
eGFR 60 to <90
N events 241 105 118 114 159 737
Model 1 1.00 (Ref) 1.26 (1.00 to 1.58) 1.24 (0.99 to 1.54) 1.14 (0.91 to 1.43) 1.47 (1.20 to 1.80) 1.08 (1.03 to 1.14)
Model 2 1.00 (Ref) 1.23 (0.98 to 1.55) 1.19 (0.96 to 1.49) 1.10 (0.88 to 1.37) 1.29 (1.05 to 1.58) 1.05 (0.99 to 1.12)
eGFR <60
N events 20 6 10 21 62 119
Model 1 1.00 (Ref) 0.72 (0.29 to 1.80) 1.00 (0.47 to 2.15) 1.01 (0.54 to 1.86) 1.10 (0.66 to 1.82) 1.19 (1.09 to 1.30)
Model 2 1.00 (Ref) 0.74 (0.28 to 1.92) 1.02 (0.46 to 2.23) 0.84 (0.43 to 1.61) 1.21 (0.70 to 2.08) 1.22 (1.11 to 1.34)
Incident cardiovascular mortality
eGFR ≥90
N events 158 55 43 39 38 333
Model 1 1.00 (Ref) 1.24 (0.91 to 1.69) 1.01 (0.72 to 1.41) 1.02 (0.72 to 1.44) 1.28 (0.90 to 1.83) 1.06 (0.94 to 1.20)
Model 2 1.00 (Ref) 1.31 (0.96 to 1.79) 0.97 (0.69 to 1.36) 1.03 (0.72 to 1.46) 1.31 (0.92 to 1.88) 1.08 (0.96 to 1.21)
eGFR 60 to <90
N events 130 54 60 74 82 400
Model 1 1.00 (Ref) 1.19 (0.86 to 1.63) 1.14 (0.84 to 1.55) 1.31 (0.98 to 1.74) 1.33 (1.01 to 1.75) 1.06 (0.98 to 1.16)
Model 2 1.00 (Ref) 1.16 (0.84 to 1.59) 1.13 (0.83 to 1.54) 1.25 (0.94 to 1.67) 1.23 (0.93 to 1.64) 1.04 (0.95 to 1.14)
Continued
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eccentric or concentric hypertrophy. This is supported by
experimental rodent models11 and observational human
studies that have shown high circulating FGF-23 to be
associated with LVH in the elderly31 and both LVH preva-
lence32,33 and incidence11 in populations with kidney
impairment. Additionally, high circulating FGF-23 has been
associated with endothelial dysfunction33–35 and inflamma-
tion.36,37 Whether FGF-23 is associated with atherosclerosis
is controversial.2,3 It is possible that phosphate excess,
which is upstream to high FGF-23, induces vascular calcifi-
cation and atherosclerosis, independent of FGF-23.2,3 Prior
work has shown elevated serum phosphorous to be associ-
ated with vascular calcification,38 myocardial fibrosis,39 the
development of LVH,40 and greater risk of incident cardio-
vascular disease41–45 (P. L. Lutsey, PhD, MPH, unpublished
data, 2014).
Enhanced understanding of the relation between FGF-23 and
cardiac pathophysiology may also provide insight into the
mechanisms through which CKD increases the risk of CHD and
HF. Levels of FGF-23 are correlated inversely with renal
function4,5 and are known to increase dramatically in advanced
CKD.4,46 It is difficult to disentangle the relations between FGF-
23 and kidney function as estimated by using GFR. However, in
the present analysis, associations between FGF-23 and incident
CHD and HF were independent of eGFR and remained present
when analyses were restricted to those with normal kidney
function (eGFR ≥90 mL/min per 1.73 m2), suggesting that
FGF-23 may have actions independent of kidney disease
quantified by reduced eGFR.We used both serumcreatinine and
cystatin to provide a better estimate of eGFR.27
The Heart and Soul Study previously reported a positive
association between FGF-23 and recurrent cardiovascular
disease.17 FGF-23 was also positively associated with risk of
incident HF and total cardiovascular events in the Cardiovas-
cular Health Study18 and with cardiovascular mortality in the
Uppsala Longitudinal Study of Adult Men.19 Both of these
cohorts are population-based studies of elderly individuals,
and in both interactions were present, whereby associations
were stronger among individuals with impaired kidney func-
tion but substantially weaker or absent among those with
normal kidney function. We observed no such interaction in
the younger ARIC study population; associations between
FGF-23 and incident HF and CHD were equally strong among
individuals with normal kidney function. In ARIC, elevated
FGF-23 was associated with an 50% greater risk of incident
CHD. This is in contrast to 3 smaller population-based studies
which have shown no relation between FGF-23 and risk of
CHD.17,18,47 FGF-23 has, however, been associated with
greater risk of atherosclerotic events among patients with
CKD.13
Identifying novel biomarkers for cardiovascular disease
may enhance our etiologic understanding and improve our
ability to identify high-risk individuals and possibly lead to new
therapeutic targets. Importantly, given the relatively modest
magnitudes of association between FGF-23 and the outcomes
presented here, it is unlikely that the use of FGF-23 would
improve risk prediction. However, because FGF-23 is physi-
ologically active (unlike cystatin C and serum creatinine,
which are markers for CKD, as opposed to causal risk factors),
it may be a potential target for intervention. Three pharma-
cologic strategies have been proposed: oral phosphate
binders, FGF-23 blocking agents, and FGF receptor antago-
nists.3 Oral phosphate binders, the only of these options
presently available, are commonly given to patients on dialysis
and those with severe renal failure and have been shown to be
effective in lowering FGF-23 levels.48,49 Clinical trials will need
to demonstrate that lowering FGF-23 is efficacious in reducing
cardiovascular disease (or possibly surrogates) and/or mor-
tality before there would be justification for the widespread
use of these agents.
Strengths of this study are the prospective design, biracial
population-based sample, detailed ascertainment of estab-
lished cardiovascular risk factors, active outcome surveil-
lance, large number of events, and corresponding power for
subgroup analyses. Also, importantly, the assay used in the
present study detects biologically active intact FGF-23, while
many prior studies have used an assay that measures inactive
C-terminal FGF-23 concentrations. Perhaps the major limita-
tion of the present study is that FGF-23 was measured in
singlicate at a single point in time and was associated with
moderate analytic error (CV 16%). As a result, regression
dilution bias may have attenuated relative hazard estimates.50
Table 4. Continued
Serum FGF-23 (pg/mL) Group 1 Group 2 Group 3 Group 4 Group 5 Per 1 SD (16.40 pg/mL)
eGFR <60
N events 7 5 7 13 37 69
Model 1 1.00 (Ref) 2.31 (0.72 to 7.39) 1.98 (0.69 to 5.69) 1.63 (0.65 to 4.12) 1.77 (0.79 to 3.99) 1.14 (1.03 to 1.25)
Model 2 1.00 (Ref) 3.23 (0.93 to 11.19) 1.85 (0.62 to 5.50) 1.41 (0.53 to 3.76) 1.51 (0.64 to 3.52) 1.05 (0.94 to 1.17)
Model 1: Adjusted for age, sex, and race. Model 2: Adjusted for model 1 plus education, physical activity, smoking, BMI, prevalent diabetes, systolic BP, HTN medication use, lipid
medication use, LDL cholesterol, and HDL cholesterol. FGF-23 indicates fibroblast growth factor-23; CHD, coronary heart disease; HF, heart failure; ARIC, Atherosclerosis Risk In
Communities; BMI, body mass index; BP, blood pressure; HTN, hypertension; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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This concept is supported by associations between FGF-23
and incident events being of greater magnitude when we
restricted our analysis to the first 5 years of follow-up. HF
events were identified through ICD codes from hospital
discharge and death certificates; thus, cases of HF that were
managed exclusively in outpatient settings would have been
missed. However, ARIC has shown HF ICD codes to have high
validity.51 Last, as with all observational studies, it is possible
that both residual and unmeasured confounding remained,
despite our attempts at adjustment.
In conclusion, in this large, population-based cohort, high
levels of FGF-23 were associated with greater risk of incident
CHD, HF, and cardiovascular mortality. These associations
were independent of traditional cardiovascular disease risk
factors and were present both in the absence of reduced
kidney function and among African Americans. These data are
of interest from a pathophysiologic perspective and suggest
the potential of FGF-23 as a target for therapeutic interven-
tion to reduce risk of CHD, HF, and cardiovascular mortality.
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